Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...
Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...
Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
Biogen aims to expand LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, with significant potential for LEQEMBI in Alzheimer's disease. Efforts include education for physicians and expanding market access ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...
While Leqembi sales performed well outside the U.S. and Skyclarys is set to grow internationally, Medicare Part D changes will hit its U.S. sales, reducing revenue by about $15–$30 million.